Literature DB >> 30554000

Solitary Fibrous Tumor/Hemangiopericytoma of Spinal Cord: A Retrospective Single-Center Study of 16 Cases.

Junwen Wang1, Kai Zhao1, Lin Han1, Liwu Jiao1, Weihua Liu1, Yu Xu1, Hongquan Niu1, Changshu Ke2, Kai Shu3, Ting Lei1.   

Abstract

OBJECTIVE: In this study, we retrospectively reviewed our experience in the surgical management of solitary fibrous tumor (SFT)/hemangiopericytomas (HPCs) of the spinal cord.
METHODS: Sixteen patients with SFT/HPCs of the spinal cord were enrolled in this study. Data on clinical presentation, radiologic findings, histopathologic features, surgical treatment, adjuvant therapy, and prognosis were retrospectively reviewed. Kaplan-Meier curves and log-rank tests were used to identify the prognostic factors for recurrence and overall survival (OS).
RESULTS: Our series included 6 men and 10 women, with a male/female ratio of 1:1.7. Magnetic resonance imaging (MRI) showed slightly hyperintense lesions on T2-weighted images for all 16 patients. All tumors showed positive immunohistochemical staining for signal transducer and activator of transcription 6. Statistical analysis of clinical data showed that age, gender, tumor location, tumor size, medullary compartment location, and Ki-67 index were not associated with recurrence and OS (P > 0.05). However, World Health Organization grade III was significantly associated with recurrence (P < 0.01). Gross total resection (GTR) and postoperative radiotherapy significantly reduced recurrence (P < 0.01 and P < 0.05), but only GTR showed remarkable benefits to improve OS (P < 0.05).
CONCLUSIONS: SFT/HPCs of spinal cord are rare neoplasms with a propensity to recur. Hyperintensity on T2-weighted magnetic resonance imaging combined with positive immunohistochemical staining for signal transducer and activator of transcription 6 are important clues for classification and differentiation of these tumors. The extent of resection, World Health Organization grade, and postoperative radiotherapy might be predictive factors for recurrence. Complete tumor resection should be sought whenever possible, and adjuvant radiotherapy is recommended after surgical resection. Moreover, regular and long-term follow-up is mandatory to monitor recurrence.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Radiotherapy; Recurrence; Solitary fibrous tumor/hemangiopericytoma; Spinal cord; Surgery; WHO grade

Mesh:

Year:  2018        PMID: 30554000     DOI: 10.1016/j.wneu.2018.12.004

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

Review 1.  Spinal Solitary Fibrous Tumors: An Original Multicenter Series and Systematic Review of Presentation, Management, and Prognosis.

Authors:  Caroline Apra; Amira El Arbi; Anne-Sophie Montero; Fabrice Parker; Steven Knafo
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

2.  Clinical Features, Management, and Prognostic Factors of Intracranial Solitary Fibrous Tumor.

Authors:  Jingdian Liu; Sisi Wu; Kai Zhao; Junwen Wang; Kai Shu; Ting Lei
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

3.  Clinical outcomes in central nervous system solitary-fibrous tumor/hemangiopericytoma: a STROBE-compliant single-center analysis.

Authors:  Yang Yu; Yu Hu; Liang Lv; Cheng Chen; Senlin Yin; Shu Jiang; Peizhi Zhou
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 2.754

4.  Cervical intramedullary solitary fibrous tumor: Case report and review of the literature.

Authors:  Ruben Rodríguez-Mena; José Piquer-Belloch; Jose Luis Llácer-Ortega; Pedro Riesgo-Suárez; Vicente Rovira-Lillo; Alain Flor-Goikoetxea-Gamo; Antonio Cremades-Mira; Raúl Mut-Pons
Journal:  Surg Neurol Int       Date:  2020-12-29

5.  Cervical solitary fibrous tumor: case report and literature review.

Authors:  Camilla Akemi Felizardo Yamada; Eduardo de Oliveira Narvaez; Vitor Nagai Yamaki; Robert Zawadzki Pfann; Iuri Santana Neville; Lázaro Luís Faria do Amaral
Journal:  BJR Case Rep       Date:  2022-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.